| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Division of Research, Kaiser Permanente Northern California, Oakland; the Women’s Health Clinical Research Center, Mount Zion Medical Center, University of California, San Francisco, California; and the Departments of Medicine and Community and Family Medicine, Clinical Research Division, Dartmouth Medical School, Hanover, New Hampshire.
Address reprint requests to: Bruce Ettinger, MD, Kaiser Permanente Medical Care Program, Division of Research, 3505 Broadway, Oakland, CA 94611-5714; E-mail: bxe{at}dor.kaiser.org.
OBJECTIVE: To examine whether women who were using postmenopausal hormone therapy (HT) before publication of Women’s Health Initiative findings about risks associated with HT had been informed about the findings once published; and to estimate how knowledge of these findings was associated with their decision to discontinue HT.
METHODS: We performed a telephone survey of 670 female members of a large health maintenance organization, aged 50–69 yr, who had regularly used HT from July 1, 2001, through June 30, 2002.
RESULTS: Most women (93%) reported hearing about the new findings; however, only 57% considered the quality of this information to be good, regardless of its source: mass media (21%), the health plan (32%), or a health care practitioner (34%). Women’s knowledge of Women’s Health Initiative findings was generally poor; 64% did not know what the findings were, 7% were unsure of their knowledge, 6% had incorrect knowledge, and 23% had correct knowledge of Women’s Health Initiative findings. On a simple, five-question, true-or-false quiz about HT risks, 30% of respondents answered four to five questions correctly. Although not well informed, 56% reported attempting to discontinue HT in the 6 to 8 months after July 2002. Our multivariable model included five statistically significant predictors of attempting to stop HT: having been sent a letter about Women’s Health Initiative findings (odds ratio [OR] 2.7; 95% confidence interval [CI] 1.8, 3.9), reporting good-quality information from media (OR 2.1; 95% CI 1.3, 3.3), having started HT for health promotion (OR 2.0; 95% CI 1.2, 3.3), using a lower-than-standard dosage of estrogen (OR 1.9; 95% CI 1.1, 3.1), and correctly answering four or more items on the HT quiz (OR 1.9; 95% CI 1.2, 2.8).
CONCLUSION: During the 6–8 months after publication of Women’s Health Initiative trial findings, most regular postmenopausal HT users tried to stop using HT, despite not being well informed about the Women’s Health Initiative findings.
This article has been cited by other articles:
|
|
 |
|
  N. Krieger Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections Int. J. Epidemiol., June 1, 2008; 37(3): 627 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Thurston, M. R. Sowers, Y. Chang, B. Sternfeld, E. B. Gold, J. M. Johnston, and K. A. Matthews Adiposity and Reporting of Vasomotor Symptoms among Midlife Women: The Study of Women's Health Across the Nation Am. J. Epidemiol., January 1, 2008; 167(1): 78 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cvoro, S. Paruthiyil, J. O. Jones, C. Tzagarakis-Foster, N. J. Clegg, D. Tatomer, R. T. Medina, M. Tagliaferri, F. Schaufele, T. S. Scanlan, et al. Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract Endocrinology, February 1, 2007; 148(2): 538 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Haimov-Kochman, E. Barak-Glantz, E. Ein-Mor, R. Arbel, A. Brzezinski, A. Milwidsky, and D. Hochner-Celnikier Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study Hum. Reprod., September 1, 2006; 21(9): 2450 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hing and K. M. Brett Changes in u.s. Prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet. Gynecol., July 1, 2006; 108(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mishra, H. Kok, R. Ecob, R. Cooper, R. Hardy, and D. Kuh Cessation of Hormone Replacement Therapy After Reports of Adverse Findings From Randomized Controlled Trials: Evidence From a British Birth Cohort Am J Public Health, July 1, 2006; 96(7): 1219 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Whelan, T. M Jurgens, and S. K Bowles Natural Health Products in the Prevention and Treatment of Osteoporosis: Systematic Review of Randomized Controlled Trials Ann. Pharmacother., May 1, 2006; 40(5): 836 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Florida Behavioral Health Research Consortium, M. A. Burg, K. Fraser, S. Gui, K. Grant, S. G. Kosch, B. Nierenberg, O. Oyama, H. Pomm, K. Sibille, et al. Treatment of Menopausal Symptoms in Family Medicine Settings following the Women's Health Initiative Findings J Am Board Fam Med, March 1, 2006; 19(2): 122 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wei, D. L. Miglioretti, M. T. Connelly, S. E. Andrade, K. M. Newton, C. L. Hartsfield, K. A. Chan, and D. S. M. Buist Changes in Women's Use of Hormones After the Women's Health Initiative Estrogen and Progestin Trial by Race, Education, and Income J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Hartsfield, M. T. Connelly, K. M. Newton, S. E. Andrade, F. Wei, and D. S. M. Buist Health System Responses to the Women's Health Initiative Findings on Estrogen and Progestin: Organizational Response J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 113 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Krieger, I. Lowy, R. Aronowitz, J. Bigby, K. Dickersin, E. Garner, J.-P. Gaudilliere, C. Hinestrosa, R. Hubbard, P. A Johnson, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives J. Epidemiol. Community Health, September 1, 2005; 59(9): 740 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ness, W. S. Aronow, E. Newkirk, and D. McDanel Use of Hormone Replacement Therapy by Postmenopausal Women After Publication of the Women's Health Initiative Trial J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2005; 60(4): 460 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. M. Buist, K. M. Newton, D. L. Miglioretti, K. Beverly, M. T. Connelly, S. Andrade, C. L. Hartsfield, F. Wei, K A. Chan, and L. Kessler Hormone Therapy Prescribing Patterns in the United States Obstet. Gynecol., November 1, 2004; 104(5): 1042 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Krebs, K. E. Ensrud, R. MacDonald, and T. J. Wilt Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review Obstet. Gynecol., October 1, 2004; 104(4): 824 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Hulley and D. Grady The WHI Estrogen-Alone Trial--Do Things Look Any Better? JAMA, April 14, 2004; 291(14): 1769 - 1771. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
